Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Warwick Effect Polymers
Cambridge, England, United Kingdom
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Warwick Effect Polymers developed advanced polymer conjugation platforms (notably PolyPEG and GlycoPol) for extending biologic half-life and drug delivery, with their technologies integrated into industry partnerships and expected to enter clinical development after acquisition by PolyTherics in 2012[7].
- Modalities
- Polymer-drug conjugate therapyBiologicSmall interfering RNAPeptides
- Industry
- Chemicals & Materials
02
Partnerships
UnileverMajor top 5 pharmaceutical company (undisclosed)BiocompatiblesSyngentaBPGeltex (Genzyme)CourtauldsICIElf AtoChem
Beyond the preview
Go deeper on Warwick Effect Polymers.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Warwick Effect Polymers.